Copyright Reports & Markets. All rights reserved.

Global Hemoderivative Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Hemoderivative Consumption Value by Type: 2020 Versus 2024 Versus 2031
    • 1.3.2 Albumin
    • 1.3.3 Immunoglobulins
    • 1.3.4 Coagulation Factors
    • 1.3.5 Others
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Hemoderivative Consumption Value by Application: 2020 Versus 2024 Versus 2031
    • 1.4.2 Therapeutics
    • 1.4.3 Excipient
    • 1.4.4 Other
  • 1.5 Global Hemoderivative Market Size & Forecast
    • 1.5.1 Global Hemoderivative Consumption Value (2020 & 2024 & 2031)
    • 1.5.2 Global Hemoderivative Sales Quantity (2020-2031)
    • 1.5.3 Global Hemoderivative Average Price (2020-2031)

2 Manufacturers Profiles

  • 2.1 Grifols
    • 2.1.1 Grifols Details
    • 2.1.2 Grifols Major Business
    • 2.1.3 Grifols Hemoderivative Product and Services
    • 2.1.4 Grifols Hemoderivative Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.1.5 Grifols Recent Developments/Updates
  • 2.2 CSL
    • 2.2.1 CSL Details
    • 2.2.2 CSL Major Business
    • 2.2.3 CSL Hemoderivative Product and Services
    • 2.2.4 CSL Hemoderivative Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.2.5 CSL Recent Developments/Updates
  • 2.3 Takeda
    • 2.3.1 Takeda Details
    • 2.3.2 Takeda Major Business
    • 2.3.3 Takeda Hemoderivative Product and Services
    • 2.3.4 Takeda Hemoderivative Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.3.5 Takeda Recent Developments/Updates
  • 2.4 Octapharma
    • 2.4.1 Octapharma Details
    • 2.4.2 Octapharma Major Business
    • 2.4.3 Octapharma Hemoderivative Product and Services
    • 2.4.4 Octapharma Hemoderivative Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.4.5 Octapharma Recent Developments/Updates
  • 2.5 CBPO
    • 2.5.1 CBPO Details
    • 2.5.2 CBPO Major Business
    • 2.5.3 CBPO Hemoderivative Product and Services
    • 2.5.4 CBPO Hemoderivative Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.5.5 CBPO Recent Developments/Updates
  • 2.6 Hualan Bio
    • 2.6.1 Hualan Bio Details
    • 2.6.2 Hualan Bio Major Business
    • 2.6.3 Hualan Bio Hemoderivative Product and Services
    • 2.6.4 Hualan Bio Hemoderivative Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.6.5 Hualan Bio Recent Developments/Updates
  • 2.7 Kedrion
    • 2.7.1 Kedrion Details
    • 2.7.2 Kedrion Major Business
    • 2.7.3 Kedrion Hemoderivative Product and Services
    • 2.7.4 Kedrion Hemoderivative Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.7.5 Kedrion Recent Developments/Updates
  • 2.8 Shanghai RAAS
    • 2.8.1 Shanghai RAAS Details
    • 2.8.2 Shanghai RAAS Major Business
    • 2.8.3 Shanghai RAAS Hemoderivative Product and Services
    • 2.8.4 Shanghai RAAS Hemoderivative Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.8.5 Shanghai RAAS Recent Developments/Updates
  • 2.9 LFB Group
    • 2.9.1 LFB Group Details
    • 2.9.2 LFB Group Major Business
    • 2.9.3 LFB Group Hemoderivative Product and Services
    • 2.9.4 LFB Group Hemoderivative Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.9.5 LFB Group Recent Developments/Updates
  • 2.10 Weiguang Bio
    • 2.10.1 Weiguang Bio Details
    • 2.10.2 Weiguang Bio Major Business
    • 2.10.3 Weiguang Bio Hemoderivative Product and Services
    • 2.10.4 Weiguang Bio Hemoderivative Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.10.5 Weiguang Bio Recent Developments/Updates
  • 2.11 Tiantan Bio
    • 2.11.1 Tiantan Bio Details
    • 2.11.2 Tiantan Bio Major Business
    • 2.11.3 Tiantan Bio Hemoderivative Product and Services
    • 2.11.4 Tiantan Bio Hemoderivative Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.11.5 Tiantan Bio Recent Developments/Updates
  • 2.12 Shuanglin Bio
    • 2.12.1 Shuanglin Bio Details
    • 2.12.2 Shuanglin Bio Major Business
    • 2.12.3 Shuanglin Bio Hemoderivative Product and Services
    • 2.12.4 Shuanglin Bio Hemoderivative Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.12.5 Shuanglin Bio Recent Developments/Updates
  • 2.13 Boya Bio
    • 2.13.1 Boya Bio Details
    • 2.13.2 Boya Bio Major Business
    • 2.13.3 Boya Bio Hemoderivative Product and Services
    • 2.13.4 Boya Bio Hemoderivative Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.13.5 Boya Bio Recent Developments/Updates
  • 2.14 Yuanda Shuyang
    • 2.14.1 Yuanda Shuyang Details
    • 2.14.2 Yuanda Shuyang Major Business
    • 2.14.3 Yuanda Shuyang Hemoderivative Product and Services
    • 2.14.4 Yuanda Shuyang Hemoderivative Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.14.5 Yuanda Shuyang Recent Developments/Updates

3 Competitive Environment: Hemoderivative by Manufacturer

  • 3.1 Global Hemoderivative Sales Quantity by Manufacturer (2020-2025)
  • 3.2 Global Hemoderivative Revenue by Manufacturer (2020-2025)
  • 3.3 Global Hemoderivative Average Price by Manufacturer (2020-2025)
  • 3.4 Market Share Analysis (2024)
    • 3.4.1 Producer Shipments of Hemoderivative by Manufacturer Revenue ($MM) and Market Share (%): 2024
    • 3.4.2 Top 3 Hemoderivative Manufacturer Market Share in 2024
    • 3.4.3 Top 6 Hemoderivative Manufacturer Market Share in 2024
  • 3.5 Hemoderivative Market: Overall Company Footprint Analysis
    • 3.5.1 Hemoderivative Market: Region Footprint
    • 3.5.2 Hemoderivative Market: Company Product Type Footprint
    • 3.5.3 Hemoderivative Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Hemoderivative Market Size by Region
    • 4.1.1 Global Hemoderivative Sales Quantity by Region (2020-2031)
    • 4.1.2 Global Hemoderivative Consumption Value by Region (2020-2031)
    • 4.1.3 Global Hemoderivative Average Price by Region (2020-2031)
  • 4.2 North America Hemoderivative Consumption Value (2020-2031)
  • 4.3 Europe Hemoderivative Consumption Value (2020-2031)
  • 4.4 Asia-Pacific Hemoderivative Consumption Value (2020-2031)
  • 4.5 South America Hemoderivative Consumption Value (2020-2031)
  • 4.6 Middle East & Africa Hemoderivative Consumption Value (2020-2031)

5 Market Segment by Type

  • 5.1 Global Hemoderivative Sales Quantity by Type (2020-2031)
  • 5.2 Global Hemoderivative Consumption Value by Type (2020-2031)
  • 5.3 Global Hemoderivative Average Price by Type (2020-2031)

6 Market Segment by Application

  • 6.1 Global Hemoderivative Sales Quantity by Application (2020-2031)
  • 6.2 Global Hemoderivative Consumption Value by Application (2020-2031)
  • 6.3 Global Hemoderivative Average Price by Application (2020-2031)

7 North America

  • 7.1 North America Hemoderivative Sales Quantity by Type (2020-2031)
  • 7.2 North America Hemoderivative Sales Quantity by Application (2020-2031)
  • 7.3 North America Hemoderivative Market Size by Country
    • 7.3.1 North America Hemoderivative Sales Quantity by Country (2020-2031)
    • 7.3.2 North America Hemoderivative Consumption Value by Country (2020-2031)
    • 7.3.3 United States Market Size and Forecast (2020-2031)
    • 7.3.4 Canada Market Size and Forecast (2020-2031)
    • 7.3.5 Mexico Market Size and Forecast (2020-2031)

8 Europe

  • 8.1 Europe Hemoderivative Sales Quantity by Type (2020-2031)
  • 8.2 Europe Hemoderivative Sales Quantity by Application (2020-2031)
  • 8.3 Europe Hemoderivative Market Size by Country
    • 8.3.1 Europe Hemoderivative Sales Quantity by Country (2020-2031)
    • 8.3.2 Europe Hemoderivative Consumption Value by Country (2020-2031)
    • 8.3.3 Germany Market Size and Forecast (2020-2031)
    • 8.3.4 France Market Size and Forecast (2020-2031)
    • 8.3.5 United Kingdom Market Size and Forecast (2020-2031)
    • 8.3.6 Russia Market Size and Forecast (2020-2031)
    • 8.3.7 Italy Market Size and Forecast (2020-2031)

9 Asia-Pacific

  • 9.1 Asia-Pacific Hemoderivative Sales Quantity by Type (2020-2031)
  • 9.2 Asia-Pacific Hemoderivative Sales Quantity by Application (2020-2031)
  • 9.3 Asia-Pacific Hemoderivative Market Size by Region
    • 9.3.1 Asia-Pacific Hemoderivative Sales Quantity by Region (2020-2031)
    • 9.3.2 Asia-Pacific Hemoderivative Consumption Value by Region (2020-2031)
    • 9.3.3 China Market Size and Forecast (2020-2031)
    • 9.3.4 Japan Market Size and Forecast (2020-2031)
    • 9.3.5 South Korea Market Size and Forecast (2020-2031)
    • 9.3.6 India Market Size and Forecast (2020-2031)
    • 9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
    • 9.3.8 Australia Market Size and Forecast (2020-2031)

10 South America

  • 10.1 South America Hemoderivative Sales Quantity by Type (2020-2031)
  • 10.2 South America Hemoderivative Sales Quantity by Application (2020-2031)
  • 10.3 South America Hemoderivative Market Size by Country
    • 10.3.1 South America Hemoderivative Sales Quantity by Country (2020-2031)
    • 10.3.2 South America Hemoderivative Consumption Value by Country (2020-2031)
    • 10.3.3 Brazil Market Size and Forecast (2020-2031)
    • 10.3.4 Argentina Market Size and Forecast (2020-2031)

11 Middle East & Africa

  • 11.1 Middle East & Africa Hemoderivative Sales Quantity by Type (2020-2031)
  • 11.2 Middle East & Africa Hemoderivative Sales Quantity by Application (2020-2031)
  • 11.3 Middle East & Africa Hemoderivative Market Size by Country
    • 11.3.1 Middle East & Africa Hemoderivative Sales Quantity by Country (2020-2031)
    • 11.3.2 Middle East & Africa Hemoderivative Consumption Value by Country (2020-2031)
    • 11.3.3 Turkey Market Size and Forecast (2020-2031)
    • 11.3.4 Egypt Market Size and Forecast (2020-2031)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
    • 11.3.6 South Africa Market Size and Forecast (2020-2031)

12 Market Dynamics

  • 12.1 Hemoderivative Market Drivers
  • 12.2 Hemoderivative Market Restraints
  • 12.3 Hemoderivative Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Hemoderivative and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Hemoderivative
  • 13.3 Hemoderivative Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Hemoderivative Typical Distributors
  • 14.3 Hemoderivative Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Hemoderivative market size was valued at US$ 9646 million in 2024 and is forecast to a readjusted size of USD 14630 million by 2031 with a CAGR of 6.3% during review period.
    In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
    Hemoderivatives, also known as blood-derived products, are therapeutic or diagnostic substances obtained from human or animal blood, primarily from plasma. Through industrial-scale fractionation, valuable proteins such as albumin, immunoglobulins, and coagulation factors are isolated for clinical use. These products are essential in treating a variety of conditions, including immune deficiencies, hemophilia, and surgical bleeding. Due to their biological origin, hemoderivatives are subject to strict regulations to ensure viral safety, traceability, and consistent quality. They play a vital role in modern medicine, especially in intensive care, transfusion therapy, and rare disease management.
    The Human Bloodm Albumin market is driven by the increasing prevalence of liver diseases, nephrotic syndrome, and hypoalbuminemia, which require albumin-based therapies. Additionally, Human Bloodm Albumin is widely used in critical care settings for treating burns, shock, and surgical recovery, boosting its demand. The expanding applications of albumin in biopharmaceuticals, including drug delivery, vaccine formulation, and regenerative medicine, further fuel market growth. Rising healthcare expenditures, improvements in plasma collection infrastructure, and growing demand in emerging markets like China and India contribute to the industry's expansion.
    However, the market faces challenges such as limited plasma supply and high production costs, as Human Bloodm Albumin is primarily derived from human plasma, which is subject to stringent donation regulations. Stringent government policies and safety concerns regarding pathogen transmission also hinder market growth. Additionally, competition from synthetic and recombinant Human Bloodm Albumin is increasing, though high production costs and market acceptance remain barriers. Overcoming supply chain constraints and advancing rHSA technologies will be crucial for sustaining growth in the global Human Bloodm Albumin market.
    The key global producers of Human Bloodm Albumin are Grifols, CSL, Takeda, Octapharma, CBPO, Hualan Bio, Kedrion, and Shanghai RAAS, with the top four manufacturers together holding 60% of the market share. The largest producer is CSL with a market share of 21.25%. In terms of consumption level, the market is mainly distributed in North America, Europe and Asia Pacific, with Asia Pacific having the highest market share of 68.63%.
    This report is a detailed and comprehensive analysis for global Hemoderivative market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Hemoderivative market size and forecasts, in consumption value ($ Million), sales quantity (MT), and average selling prices (US$/Kg), 2020-2031
    Global Hemoderivative market size and forecasts by region and country, in consumption value ($ Million), sales quantity (MT), and average selling prices (US$/Kg), 2020-2031
    Global Hemoderivative market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (MT), and average selling prices (US$/Kg), 2020-2031
    Global Hemoderivative market shares of main players, shipments in revenue ($ Million), sales quantity (MT), and ASP (US$/Kg), 2020-2025
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Hemoderivative
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Hemoderivative market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Grifols, CSL, Takeda, Octapharma, CBPO, Hualan Bio, Kedrion, Shanghai RAAS, LFB Group, Weiguang Bio, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Hemoderivative market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Albumin
    Immunoglobulins
    Coagulation Factors
    Others
    Market segment by Application
    Therapeutics
    Excipient
    Other
    Major players covered
    Grifols
    CSL
    Takeda
    Octapharma
    CBPO
    Hualan Bio
    Kedrion
    Shanghai RAAS
    LFB Group
    Weiguang Bio
    Tiantan Bio
    Shuanglin Bio
    Boya Bio
    Yuanda Shuyang
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Hemoderivative product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Hemoderivative, with price, sales quantity, revenue, and global market share of Hemoderivative from 2020 to 2025.
    Chapter 3, the Hemoderivative competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Hemoderivative breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Hemoderivative market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Hemoderivative.
    Chapter 14 and 15, to describe Hemoderivative sales channel, distributors, customers, research findings and conclusion.

    Buy now